24 unknown, 13 completed, 6 recruiting, 3 not yet recruiting. 35 Phase 2, 11 Phase 3, 7 Phase 1, 1 Not applicable, 1 Phase 4.
Follow nedaplatin: new trials by email Literature Review of nedaplatin trials Research Report on nedaplatin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ipromlimab and Tuvonralimab Combined With Albumin-Bound Paclitaxel and Nedaplatin as Neoadjuvant Therapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma lpromlimab and Tuvonralimab lpromlimab and Tuvonralimab Combined with Albumin-Bound Paclitaxel and Nedaplatin - Locally Advanced, Resectable | Phase 2 | Active not recruiting | Sun Yat-sen University | 62 | 2025-12-17 | 2026-01-28 |
| Tislelizumab Combined With Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma Followed by CRT or Surgery Tislelizumab, Albumin-Bound Paclitaxel, cis-platinum - Esophagus Cancer | Phase 2 | Not yet recruiting | Fujian Cancer Hospital | 60 | 2025-08-01 | 2025-07-20 |
| Tislelizumab Combined With Chemotherapy for the Perioperative Treatment of Esophageal Squamous Carcinoma Tislelizumab, albumin-bound paclitaxel, Nedaplatin - Esophagus Cancer | Phase 2 | Not yet recruiting | The First Affiliated Hospital of Xiamen University | 26 | 2025-07-30 | 2025-06-13 |
| A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors WJB001 Capsules+Paclitaxel/Paclitaxel-albumin, WJB001 Capsules+carboplatin/Nedaplatin, WJB001 Capsules+Paclitaxel+carboplatin - Advanced Solid Tumor | Phase 1 / Phase 2 | Recruiting | Wigen Biomedicine Technology (Shanghai) Co., Ltd. | 86 | 2025-07-10 | 2026-09-17 |
| Phase II Trial of Albumin-Bound Paclitaxel Combined With Nedaplatin (TP) Via Hepatic Arterial Infusion for Advanced Breast Cancer Patients With Liver Metastases After Failure of Standard Therapy Abraxane, Nedaplatin - Hepatic Artery Infusion, Liver Metastasis of Breast Cancer | Phase 2 | Recruiting | Zhejiang Cancer Hospital | 30 | 2025-02-01 | 2025-12-16 |
| A Study of Adebrelimab in Combination with Chemo with or Without Bevacizumab Neoadjuvant Therapy for Resectable NSCLC Adebellizumab, Bevacizumab, Platinum-based chemotherapy - Resectable Lung Non-Small Cell Carcinoma | Phase 2 | Recruiting | The First Affiliated Hospital of Guangzhou Medical University | 60 | 2024-09-24 | 2025-01-15 |
| Adebrelimab Combined With Albumin Paclitaxel and Nedaplatin as Neoadjuvant Therapy for Locally Advanced Resectable ESCC Adebrelimab, albumin paclitaxel, Nedaplatin - Esophageal Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | Harbin Medical University | 65 | 2024-07-30 | 2024-07-18 |
| Fruquintinib as First Line Treatment in Patients With Recurrent Esophageal Squamous Cell Carcinoma Fruquintinib Combined With Camrelizumab, Paclitaxel Liposome and Nedaplatin - Esophageal Squamous Cell Carcinoma | Phase 1 / Phase 2 | Unknown | The First Affiliated Hospital with Nanjing Medical University | 36 | 2023-08-25 | 2023-08-24 |
| Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC Pembrolizumab, Cisplatin, Carboplatin - Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy | Phase 3 | Recruiting | Beijing Tongren Hospital | 272 | 2023-05-01 | 2023-10-30 |
| Advanced First-line Treatment of Short-term Postoperative Progression of Head and Neck Squamous Cell Carcinoma Camrelizumab, Cisplatin, Carboplatin - Head and Neck Squamous Cell Carcinoma | Phase 2 | Unknown | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 46 | 2023-03-01 | 2023-12-20 |
| PPIO-004 Clinical Application of Efficacy Prediction Model Based on Epigenomics Sequencing Technology in Neoadjuvant Immunotherapy for Esophageal Cancer Tislelizumab - Esophageal Squamous Cell Carcinoma | Phase 2 | Completed | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | 118 | 2023-01-13 | 2025-08-24 |
| Nimotuzumab Combined With Neoadjuvant Chemotherapy in the Treatment of Resectable LA HNSCC Nimotuzumab Combined With Neoadjuvant Chemotherapy - Head and Neck Squamous Cell Carcinoma | Phase 2 | Unknown | Xijing Hospital | 55 | 2022-07-01 | 2022-07-05 |
| Induction Tislelizumab Combined With Chemotherapy Followed by Definitive Chemoradiotherapy in the Treatment of Locally Unresectable Esophageal Squamous Cell Carcinoma Tislelizumab, Albumin paclitaxel, Nedaplatin - Immunotherapy Esophagus Cancer | Phase 2 | Recruiting | Fuzhou General Hospital | 93 | 2022-05-31 | 2024-02-07 |
| First-Line Treatment for Advanced Non-squamous Non-Small-Cell Lung Cancer With Negative Driver Gene: a Single-center, Single-Arm Trial Sintilimab - Advanced Non-squamous Non-Small-Cell Lung Cancer | Phase 3 | Unknown | Qianfoshan Hospital | 60 | 2021-12-01 | 2022-12-13 |
| Clinical Study of Radiotherapy Combined With Nedaplatin Contrast and Cisplatin for the Treatment of Locally Advanced Head and Neck Squamous Carcinoma Nedaplatin, Cisplatin - Head and Neck Squamous Carcinoma | Phase 2 | Unknown | Guiyang Medical University | 164 | 2021-09-01 | 2021-09-09 |
| Efficacy and Safety of Toripalimab Combined With AP-induced Chemotherapy Followed in Non-metastatic IVB Hypopharyngeal Cancer Cisplatin/Nedaplatin, albumin paclitaxel - Hypopharyngeal Cancer | Phase 2 | Unknown | Chinese PLA General Hospital | 30 | 2021-07-01 | 2024-02-20 |
| Nedaplatin in Treatment for Nasopharyngeal Carcinoma Docetaxel, nedaplatin, fluorouracil, IMRT, Nedaplatin - Nasopharyngeal Carcinoma | Phase 2 | Completed | Affiliated Cancer Hospital & Institute of Guangzhou Medical University | 32 | 2021-05-01 | 2022-05-10 |
| Toripalimab Plus Neoadjuvant Chemotherapy Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma Toripalimab, Paclitaxel-albumin, Nedaplatin - Esophageal Squamous Cell Carcinoma | Phase 2 | Unknown | Sun Yat-sen University | 124 | 2021-02-20 | 2024-02-09 |
| Neoadjuvant Therapy of PD-1 Blockade Combined With Chemotherapy for Esophageal Carcinoma PD-1 blockade, Albumin paclitaxel, Carboplatin/Nedaplatin - Esophageal Carcinoma, Neoadjuvant Immunotherapy | Phase 1 / Phase 2 | Unknown | Beijing Friendship Hospital | 89 | 2020-10-29 | 2023-03-21 |
| Nedaplatin Versus Cisplatin in Treatment for Nasopharyngeal Carcinoma Docetaxel, nedaplatin, fluorouracil, Docetaxel, cisplatin, fluorouracil, Nedaplatin - Nasopharyngeal Carcinoma | Phase 3 | Recruiting | Affiliated Cancer Hospital & Institute of Guangzhou Medical University | 352 | 2020-08-01 | 2022-05-10 |
Showing 20 of 49. Sign in to see all of them.
Nasopharyngeal Carcinoma (12) · Esophageal Neoplasms (10) · Esophageal Squamous Cell Carcinoma (8) · Carcinoma, Non-Small-Cell Lung (3) · Carcinoma, Squamous Cell (3) · Squamous Cell Carcinoma of Head and Neck (3) · Uterine Cervical Neoplasms (3) · Recurrence (2) · Central Nervous System Neoplasms (1) · Head and Neck Neoplasms (1) · Hypopharyngeal Neoplasms (1) · Lymphoma (1) · Neoplasms (1) · Ovarian Neoplasms (1) · Small Cell Lung Carcinoma (1)
Sun Yat-sen University (7) · Chinese Academy of Medical Sciences (4) · Daping Hospital and the Research Institute of Surgery of the Third Military Medical University (3) · Affiliated Cancer Hospital & Institute of Guangzhou Medical University (2) · Jiangsu Cancer Institute & Hospital (2) · Zhejiang Cancer Hospital (2) · Beijing Friendship Hospital (1) · Beijing Tongren Hospital (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Changjie Huang (1) · Chinese PLA General Hospital (1) · Daiichi Sankyo Co., Ltd. (1) · First Affiliated Hospital of Guangxi Medical University (1) · Fujian Cancer Hospital (1) · Fuzhou General Hospital (1)
China (38) · Japan (2)
Jinquan Liu, M.D (2) · Zefen Xiao, MD (2) · Changjie Huang (1) · Degan Lu, professor (1) · Feng Jin, Bachelor (1) · Guopei Zhu, M.D. (1) · HaiQiang Mai, MD,Ph.D (1) · Hui Liu, Prof. (1) · Hui Liu, Professor (1) · Jianqun Ma, MD (1) · Jianxing He (1) · Jing Huang, MD (1) · Jingbo Wang (1)
PMID 10235156, PMID 11870157, PMID 14967459, PMID 19930599, PMID 21277552, PMID 21462364, PMID 21684205, PMID 22555809, PMID 22565611, PMID 22646630, PMID 24609941, PMID 25691612, PMID 29229461, PMID 29501366, PMID 30017831, PMID 30119083, PMID 30285222, PMID 30876442, PMID 30955977, PMID 31378236, PMID 31402780, PMID 31560378, PMID 32070309, PMID 32781263, PMID 32997907, PMID 33314747, PMID 34358724, PMID 34928359, PMID 36158699, PMID 40242562, PMID 41496409, PMID 41878954, PMID 42498484